13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Guardant Health GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.

Sources StockAnalysis company profile stockanalysis.com
Medical Specialities

Company profile

Business mix

  • The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers.
  • It also provides Shield blood test for colorectal cancer screening in adults.
  • Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic.
  • Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within diagnostics & research?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -1.42% Buyback -3.2%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.4% $356.5M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 0 Last 3 13F filing periods
Net reducers 1 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $0 Estimated from net added shares
Reduction amount $87.8M Estimated from net reduced shares
Net share change / base shares -19.8% -950,740 / 4,809,786
Baillie Gifford legacy James Anderson 3 filing periods
13F 2025-09-30 Filed 2025-10-31
Minor increase Shares 6.6% 13F value change +$70.1M
13F 2025-12-31 Filed 2026-01-23
Minor reduction Shares -4.6% 13F value change +$179.1M
13F 2026-03-31 Filed 2026-05-08
Major reduction Shares -21.1% 13F value change -$143.0M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 4,809,786 Last 3 periods -950,740 (-19.8%) Total shares 3,859,046 Value $356.5M

Recent mentions

No public mentions.